1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hana Pharm Co., Ltd.

Hana Pharm Co., Ltd.

KKRX:293480
8,260.00
KRW
-40.00
(-0.48%)
996.41EPS
8.80P/E
155.61BMarket Cap
Nov 18Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14,600.79
11,689.5
10,480.25
9,499.71
10,249.47
11,771.56
12,187.23
12,975.27
13,021.96
13,833.26
14,130.82
Basic EPS, GAAP
2,043.64
2,039.09
1,794.55
1,616.36
860.91
1,679
1,405
1,291
1,228
507
997.87
Free Cash Flow per Basic Share
289.26
1,806.96
1,509.69
-115.07
-90.21
-548.71
-282.35
215.06
698.68
-1,271.01
-3,143.06
Dividend per Share
- -
85.84
206.09
257.43
418.26
480.8
509.97
510.02
509.85
509.58
- -
Book Value per Share
3,113.61
4,542.07
11,597.57
12,734.16
13,430.59
14,561.19
15,514.73
16,068.97
17,871.98
17,683.79
18,718.81
Tangible Book Value per Share
3,002.15
4,352.19
11,297.2
12,417.44
12,969.69
13,819.12
14,821.65
15,236.45
16,961.48
16,668.33
17,676.52
Basic Weighted Avg Shares
9
12
15
18
17
17
17
17
17
17
18
Sales/Revenue/Turnover
124,535
139,331
152,833
166,347
177,306
196,407
210,845
224,457
225,340
239,504
247,312
Operating Margin (%)
19.01
22.92
21.96
20.18
17.86
18.33
14.78
12.04
11.16
10.78
11.55
Depreciation Expense
3,678
3,522
3,563
4,201
4,995
5,762
6,495
7,647
7,717
11,157
13,042
Net Income, GAAP
17,431
24,305
26,170
28,304
14,893
28,014
24,307
22,333
21,250
8,778
17,464
Effective Tax Rate (%)
20.59
21.51
19.06
18.81
47.74
21.85
20.87
19.97
16.32
52.19
37.66
Profit Margin (%)
14
17.44
17.12
17.01
8.4
14.26
11.53
9.95
9.43
3.67
7.06
Working Capital
26,381
30,685
141,944
125,230
113,557
99,610
58,823
46,295
74,167
53,657
61,648
LT Debt
21,155
6,214
1,568
1,773
897
1,230
22,132
1,599
24,359
24,116
34,326
Total Equity
55,485
81,298
205,386
220,332
232,382
251,901
268,397
277,985
309,176
313,409
331,752
Return on Invested Capital (%)
- -
24.1
16.32
12.13
6.96
11
8.54
6.99
6.44
3.43
4.72
Return on Capital (%)
- -
25.54
16.49
13.01
6.45
11.23
8.77
7.36
6.61
2.47
4.68
Return on Common Equity (%)
- -
35.63
18.28
13.3
6.58
11.57
9.34
8.17
7.24
2.82
5.44

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
34,603
42,471
35,793
LT Borrowings
22,765
22,390
32,815
LT Finance Leases
1,351
1,210
1,511
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
198,851
161,102
155,607

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
117,816
113,184
126,064
Cash, Cash Equivalents & STI
13,472
6,573
17,285
Accounts Receivable, Net
40,207
39,143
- -
Inventories
58,067
60,991
62,885
Total Current Liabilities
64,159
80,647
64,415
Payables & Accruals
- -
- -
- -
ST Debt
34,603
42,471
35,793
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.22%
1.37%
Free Cash Flow
- -
41.36%
-282.01%
Net Income, GAAP
- -
0.64%
-58.69%
Sales/Revenue/Turnover
- -
6.25%
6.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
57,066
53,498
57,250
57,525
225,340
2025
57,481
57,879
63,774
60,371
239,504
2026
62,264
60,904
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
351
291
171
415.64
1,228
2025
245
320
-246.17
188.93
507
2026
565.47
477
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
509.85
2025
- -
- -
- -
- -
509.58
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tae-Hong Choi
Full Time Employees
708
Sector
Health technology
Industry
Pharmaceuticals: major
Address
EK-Tower Hwaseong-si GY South Korea 06162
IPO Date
Oct 2, 2018
Website
hanaph.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hana Pharm Co., Ltd. develops, manufactures and markets specialty pharmaceutical products primarily in South Korea and internationally. The company offers anesthetics including remimazolam under the brand Byfavo; narcotic analgesics; antiemetics; muscle relaxants; cardiovascular drugs such as hypertension, hyperlipidemia and blood circulation improvement medicines; gastrointestinal drugs including peptic ulcer treatments and antispasmodics; respiratory system products; antibiotics; dermatology analgesics; urology treatments; osteoporosis medications; central nervous system drugs; and analgesics, antipyretics and anti-inflammatory drugs. Founded in 1978 and headquartered in Seoul, South Korea, Hana Pharm operates manufacturing facilities in Hwaseong-si, Gyeonggi-do, and a research laboratory in Seongnam-si, Gyeonggi-do, with approximately 730 employees. In recent developments, Hana Pharm launched Byfavo (remimazolam) in South Korea following regulatory approval and extended its license agreement with Paion AG to include Southeast Asia markets comprising Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam, securing an upfront payment of EUR 1.5 million plus potential milestones up to EUR 4.2 million and royalties; the company also executed an option agreement with Bold Therapeutics for exclusive development and commercialization rights to BOLD-100, a ruthenium-based oncology drug, in South Korea to support clinical trials in gastric, pancreatic, colorectal and bile duct cancers.